Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results
22 Février 2022 - 1:00PM
Business Wire
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage
biopharmaceutical company developing and delivering novel
epigenetic therapies, today announced that management will host a
conference call to discuss its fourth quarter and full year 2021
financial results and provide a business update on Tuesday, March
1, 2022 at 8:30 a.m. ET.
To participate in the conference call, please dial (877)
844-6886 (domestic) or (970) 315-0315 (international) and refer to
conference ID 4082815. A live webcast will be available in the
investor section of the company's website at www.epizyme.com, and
will be archived for 60 days following the call.
About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage
biopharmaceutical company committed to its mission of rewriting
treatment for cancer through novel epigenetic medicines. The
Company is focused on creating medicines that are targeted at
specific causes of diseases, that are orally administered,
tolerable, easy to take and based on a deep understanding of the
patients that may benefit from them. The Company aspires to change
the standard-of-care for patients and physicians by developing
medicines with fundamentally new mechanisms of action. For more
information, visit www.epizyme.com.
TAZVERIK® is a registered trademark of Epizyme, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220222005218/en/
Media: Erin Graves media@epizyme.com (617) 500-0615
Investors: Caitlin Stern Real Chemistry
cstern@realchemistry.com
Epizyme (NASDAQ:EPZM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Epizyme (NASDAQ:EPZM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Epizyme Inc (NASDAQ): 0 recent articles
Plus d'articles sur Epizyme, Inc.